TY - JOUR AU - Oppong, Bridget A. AU - Gupta, Surupa Sen AU - Gary, Monique AU - Wehner, Patricia AU - Mete, Mihriye AU - Zhao, Danjing AU - Seevaratnam, Sulakshana AU - Rudra, Sonali AU - Willey, Shawna C. PY - 2017 TI - 21-gene recurrence assay in patients receiving intraoperative radiotherapy: are “favorable” characteristics a surrogate for low recurrence? JF - Gland Surgery; Vol 6, No 6 (December 13, 2017): Gland Surgery Y2 - 2017 KW - N2 - Background: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC. Methods: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013–2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy. Results: The mean age was 68. Tumors were stage Ia (86.6%), 3.6% Ib and 9.8% IIa. Of 50 patients (61.0%) with RS testing, 72% (n=36) were low risk (RS 0–17), with 28% (n=14) at intermediate risk (RS 18–30). The 39% (n=32) of patients without RS testing, were more likely to have smaller tumors (1.3 vs. 0.9 cm) and age >70 (P Conclusions: Most patients selected for IORT based on clinical features were indeed low risk based on RS. Given the limited long-term clinical outcome and safety data of this technique, additional investigation is needed. UR - https://gs.amegroups.org/article/view/16202